 |
|
|
| |
Effect of Baseline Factors on Response to the Fixed-Dose Combination Of Daclatasvir, Asunaprevir and Beclabuvir in Non-Cirrhotic Patients with HCV Genotype 1 Infection
|
| |
| |
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
Reddy KR,1 Beavers KL,2 Gordon S,3 Harrison S,4 Reau N,5 Yozviak J,6 de Ledinghen V,7 Conway B,8 Tse E,9 Bhore R,10 Boparai N,10 Hughes EA,10 Swenson ES,11 Yin PD11
1University of Pennsylvania, Philadelphia, PA, USA; 2Medical University of South Carolina, Charleston, SC, USA; 3Henry Ford Health System, Detroit, MI, USA; 4Brooke Army Medical Center, San Antonio, TX, USA; 5University of Chicago Medical Center, Chicago, IL, USA; 6Lehigh Valley Health Network, Allentown, PA, USA; 7Hopital Du Haut-Leveque, Pessac, France; 8Vancouver Infectious Diseases Centre, Vancouver, Canada; 9Royal Adelaide Hospital, Adelaide, Australia; 10Bristol-Myers Squibb Research and Development, Princeton, NJ, USA; 11Bristol-Myers Squibb Research and Development, Wallingford, CT, USA
|
| |
|
|
|
|
|
